Although targeting JMJD3 has good antitumor effect, the role of JMJD3 and UTX in the same kind of tumor is not exactly the same (177), and the potential side effects of GSK-J4 should be taken into careful consideration. This evidence concerns the gene KDM6B and neoplasm.